Recombinant Human GRIA3 protein

中文名： AMPA离子能谷氨酸受体3(GRIA3)重组蛋白
别名： GRIA3；GluA3；GLUR3；GLURC；Glutamate receptor 3

货号: PA1000-7690

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	GRIA3
Uniprot No	P42263
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	151-250aa
氨基酸序列	SLLGHYKWEKFVYLYDTERGFSILQAIMEAAVQNNWQVTARSVGNIKDVQEFRRIIEEMDRRQEKRYLIDCEVERINTILEQVVILGKHSRGYHYMLANL
预测分子量	14.0kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于GRIA3重组蛋白的3篇参考文献示例(注：文献为虚拟示例，仅供参考格式)：

---

1. **文献名称**：*Recombinant Expression and Functional Characterization of the Human GRIA3 Glutamate Receptor Subunit*

**作者**：J. Smith et al.

**摘要**：研究通过哺乳动物细胞表达系统成功重组表达了人源GRIA3蛋白，并利用电生理记录验证其形成功能性AMPA受体通道，揭示了其对谷氨酸和调节剂的选择性响应特性。

2. **文献名称**：*Structural Insights into GRIA3 Extracellular Domain by Cryo-EM*

**作者**：L. Chen & M. Tanaka

**摘要**：通过冷冻电镜技术解析了重组GRIA3胞外域的三维结构，阐明了其配体结合口袋的构象变化，为设计靶向AMPA受体的神经疾病药物提供了结构基础。

3. **文献名称**：*GRIA3 Mutations Alter Synaptic Plasticity: Evidence from Recombinant Protein Models*

**作者**：R. Kumar et al.

**摘要**：利用重组GRIA3蛋白及突变体，结合海马神经元实验，发现特定突变(如R450Q)显著降低受体脱敏速率，提示其在神经发育障碍中的潜在病理机制。

---

(实际文献需通过PubMed、Web of Science等数据库检索关键词“GRIA3 recombinant protein”或“GluA3 expression”获取。)

背景信息

The GRIA3 gene encodes the GluA3 subunit of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, a class of ionotropic glutamate receptors critical for fast excitatory synaptic transmission in the central nervous system. These receptors mediate the majority of rapid neurotransmission and play essential roles in synaptic plasticity, learning, and memory. GRIA3-derived GluA3 forms tetrameric ligand-gated ion channels, typically in combination with other AMPA receptor subunits (GluA1-4), to regulate calcium permeability and channel kinetics. Dysregulation of GluA3 has been implicated in neurological disorders, including epilepsy, intellectual disability, and neuropsychiatric conditions like schizophrenia and autism spectrum disorders.

Recombinant GRIA3 protein refers to the purified GluA3 subunit produced through heterologous expression systems (e.g., HEK293 or insect cells) using genetic engineering techniques. This approach enables controlled production of functional domains or full-length proteins with post-translational modifications resembling native forms. Researchers commonly employ recombinant GRIA3 to study receptor assembly, ligand-binding mechanisms, and subunit-specific contributions to synaptic physiology. It serves as a vital tool for structural studies (e.g., X-ray crystallography, cryo-EM), drug discovery targeting AMPA receptors, and functional assays exploring receptor trafficking or allosteric modulation. The protein's availability has advanced understanding of glutamate receptor biology and pathophysiological mechanisms, particularly in diseases associated with GRIA3 mutations or altered expression. Recent studies also utilize recombinant GluA3 to develop subtype-selective therapeutics and investigate mechanisms of receptor endocytosis in neurodegenerative contexts.